These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28000523)

  • 41. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AhR Activation Leads to Massive Mobilization of Myeloid-Derived Suppressor Cells with Immunosuppressive Activity through Regulation of CXCR2 and MicroRNA miR-150-5p and miR-543-3p That Target Anti-Inflammatory Genes.
    Neamah WH; Singh NP; Alghetaa H; Abdulla OA; Chatterjee S; Busbee PB; Nagarkatti M; Nagarkatti P
    J Immunol; 2019 Oct; 203(7):1830-1844. PubMed ID: 31492743
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.
    Stone ML; Beatty GL
    Pharmacol Ther; 2019 Sep; 201():202-213. PubMed ID: 31158393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy.
    Dong Y; Fu R; Chen J; Zhang K; Ji M; Wang M; Jiang H; Ye W; Hu J; Li Y; Jin J; Chen X; Xu H
    J Med Chem; 2021 Nov; 64(22):16626-16640. PubMed ID: 34676759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells.
    Xie Z; Ago Y; Okada N; Tachibana M
    J Pharmacol Sci; 2018 Aug; 137(4):359-365. PubMed ID: 30177294
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
    Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
    Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CXCR2: a target for pancreatic cancer treatment?
    Hertzer KM; Donald GW; Hines OJ
    Expert Opin Ther Targets; 2013 Jun; 17(6):667-80. PubMed ID: 23425074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What is recent in pancreatic cancer immunotherapy?
    Niccolai E; Prisco D; D'Elios MM; Amedei A
    Biomed Res Int; 2013; 2013():492372. PubMed ID: 23509731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
    Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
    Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.
    Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
    J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
    Busch-Petersen J
    Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
    Liu B; Song Y; Liu D
    J Hematol Oncol; 2017 Dec; 10(1):174. PubMed ID: 29195503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
    Bear AS; Vonderheide RH; O'Hara MH
    Cancer Cell; 2020 Dec; 38(6):788-802. PubMed ID: 32946773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
    Yoo B; Jordan VC; Sheedy P; Billig AM; Ross A; Pantazopoulos P; Medarova Z
    Sci Rep; 2019 Mar; 9(1):4712. PubMed ID: 30886310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease.
    Ryu JK; Cho T; Choi HB; Jantaratnotai N; McLarnon JG
    J Neuroinflammation; 2015 Aug; 12():144. PubMed ID: 26255110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.